$SCNIJun 15, 2026, 4:30 PM ETAI processed6-K
SCNI completes Recipharm Israel acquisition; Q1 revenue $489k, net income $3.577M on $6.156M bargain purchase
AI Summary
SCNI filed SEC Form 6-K. For Q1 2026 the company reported $489k revenue, cost of revenues $1.607M, operating loss $2.467M and GAAP net income $3.577M primarily reflecting a $6.156M non‐cash bargain purchase gain; cash, cash equivalents and restricted cash were $3.114M as of March 31, 2026. As noted in a footnote, ordinary shares outstanding increased to 20,677,532,000 (representing 5,169,383 ADS) as of June 10, 2026.
Positives
- Acquisition of Recipharm Israel adds a Yavne manufacturing site and a strategic commercial collaboration with Recipharm AB, expanding CDMO capabilities and customer pipeline
- Recognized a $6.156M non-cash bargain purchase gain tied to the acquisition, producing GAAP net income of $3.577M for Q1
- Cash and restricted cash totaled $3.114M as of March 31, 2026, up from period start
Negatives
- Quarterly revenue was small ($489k) and declined from $586k year-over-year
- Operating loss widened to $2.467M due to expanded CDMO operations and a change in cost-allocation that shifted employee/facility costs into cost of revenues
- Planned funding for R&D and CDMO expansion depends on multiple grant applications with decisions expected in H2 2026 (outcome uncertain)